Retail pharmaceutical sales in Moldova grew by almost 60% to $49.6 million in the first six months of this year, while the number of packs sold increased by 10%, reports Business-Credit, a Kiev-based market research firm. Imported products represented the overwhelming majority (96%) of all medicines on the market, with sales of $47.7 million (+58%).
Retail pharmaceutical sales in Moldova grew by almost 60% to $49.6 million in the first six months of this year, while the number of packs sold increased by 10%, reports Business-Credit, a Kiev-based market research firm. Imported products represented the overwhelming majority (96%) of all medicines on the market, with sales of $47.7 million (+58%).
Sales of prescription pharmaceuticals, which accounted for 60% of the total, increased by more than 60% to $29.7 million and...
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
